Stockscreener 앱 받기
59.18
0.52%
0.16
전일 마감가:
$59.02
열려 있는:
$59.56
하루 거래량:
583.83K
Relative Volume:
0.16
시가총액:
$26.24B
수익:
$2.44B
순이익/손실:
$1.36B
주가수익비율:
31.00
EPS:
1.9093
순현금흐름:
$574.14M
1주 성능:
+1.98%
1개월 성능:
+9.30%
6개월 성능:
+46.86%
1년 성능:
+62.15%
1일 변동 폭
$59.07
$59.72
1주일 범위
$56.90
$59.72
52주 변동 폭
$34.08
$59.72
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
59.20 | 26.16B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
480.17 | 120.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
663.27 | 68.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.97 | 57.84B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.23 | 40.13B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.02 | 35.88B | 4.29B | 577.22M | 641.34M | 4.2086 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 업그레이드 | UBS | Neutral → Buy |
| 2025-09-30 | 개시 | Goldman | Buy |
| 2025-05-16 | 개시 | Morgan Stanley | Overweight |
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
RPHC5035520 Bond Risk Profile - TradingView
RPHC5237354 Bond Coupon Profile — Rate & Payments - TradingView
Royalty Pharma (NASDAQ:RPRX) Reaches New 1-Year HighShould You Buy? - MarketBeat
RPHC5237354 Bond Profile — Key Metrics - TradingView
RPHC5035520 Bond Coupon Profile — Rate & Payments - TradingView
Neurimmune sells a portion of its royalty interest in cliramitug to Royalty Pharma - marketscreener.com
Bank of New York Mellon Corp Reduces Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
177,500 Shares in Royalty Pharma PLC $RPRX Acquired by Andra AP fonden - MarketBeat
Press Release: Royalty Pharma Declares Third Quarter 2026 Dividend - 富途牛牛
RPHC6166013 Bond Risk Profile - TradingView
RPHC6166013 Bond Profile — Key Metrics - TradingView
Royalty Pharma acquires royalty stake in AstraZeneca drug - Investing.com UK
Royalty Pharma PLC (RPRX) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma acquires royalty stake in AstraZeneca drug By Investing.com - Investing.com South Africa
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune - marketscreener.com
Royalty Pharma deal includes $125M upfront for heart antibody - Stock Titan
Royalty Pharma PLC $RPRX Shares Bought by Swiss National Bank - MarketBeat
Mediolanum International Funds Ltd Sells 40,296 Shares of Royalty Pharma PLC $RPRX - MarketBeat
SEB Asset Management AB Invests $12.97 Million in Royalty Pharma PLC $RPRX - MarketBeat
California Public Employees Retirement System Cuts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Holdings Lowered by AlTi Global Inc. - MarketBeat
How (RPRX) Movements Inform Risk Allocation Models - Stock Traders Daily
Hsbc Holdings PLC Acquires 1,486,020 Shares of Royalty Pharma PLC $RPRX - MarketBeat
RPHC5824521 Bond Profile — Key Metrics - TradingView
Royalty Pharma declares $0.235 dividend - MSN
US78081BAP8 Bond Coupon Profile — Rate & Payments - TradingView
RPHC5237916 Bond Coupon Profile — Rate & Payments - TradingView
RPHC5237916 Bond Profile — Key Metrics - TradingView
RPHC6166012 Bond Profile — Key Metrics - TradingView
RPHC6166012 Bond Risk Profile - TradingView
Royalty Pharma declares $0.235 quarterly dividend By Investing.com - Investing.com South Africa
Royalty Pharma declares $0.235 quarterly dividend - Investing.com UK
Royalty Pharma Maintains Quarterly Dividend at $0.235 a Share, Payable on Sept. 10 to Shareholders of Record on Aug. 14 - marketscreener.com
Royalty Pharma Announces Third Quarter 2026 Dividend of $0.235 per Class A Ordinary Share - Quiver Quantitative
Royalty Pharma plc (RPRX) Declares $0.235 Quarterly Dividend; 1.6% Yield - StreetInsider
Royalty Pharma plc Declares Third Quarter 2026 Dividend, Payable on September 10, 2026 - marketscreener.com
Royalty Pharma stock hits all-time high at 58.85 USD By Investing.com - Investing.com South Africa
RPHC6166012 Bond Coupon Profile — Rate & Payments - TradingView
Royalty Pharma (NASDAQ:RPRX) Sets New 12-Month HighHere's Why - MarketBeat
Royalty Pharma stock hits all-time high at 58.85 USD - Investing.com
Royalty Pharma PLC $RPRX Shares Sold by C WorldWide Group Holding A S - MarketBeat
RPHC5824522 Bond Coupon Profile — Rate & Payments - TradingView
Royalty Pharma to announce Q2 2026 financial results on August 5 - scanx.trade
Royalty Pharma schedules 8 a.m. webcast for Aug. 5 results - Stock Titan
RPHC5222527 Bond Profile — Key Metrics - TradingView
Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026 - Yahoo Finance
US78081BAN3 Bond Coupon Profile — Rate & Payments - TradingView
US78081BAN3 Bond Risk Profile - TradingView
Royalty Pharma PLC $RPRX Shares Sold by J. Safra Sarasin Holding AG - MarketBeat
Calamos Advisors LLC Takes Position in Royalty Pharma PLC $RPRX - MarketBeat
RPHC5824522 Bond Risk Profile - TradingView
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
로열티 파마 주식 (RPRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hite Christopher | EVP & Chairman, Partnering |
Jun 30 '26 |
Sale |
56.52 |
100,000 |
5,651,813 |
459,399 |
| Hite Christopher | EVP & Chairman, Partnering |
Jun 30 '26 |
Sale |
56.46 |
30,000 |
1,693,658 |
40,000 |
0.90%
자본화:
|
볼륨(24시간):